Trial Profile
Study of JZP-110 for excessive sleepiness in Parkinson's disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2017
Price :
$35
*
At a glance
- Drugs Solriamfetol (Primary)
- Indications Narcolepsy
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 17 Feb 2017 New trial record
- 08 Feb 2017 According to Jazz Pharmaceuticals plc media release, first patient has been enrolled and JZP-110 has orphan drug designation in the United States for narcolepsy